Almirall SA : Q4 EBITDA in line. NP again below on impairments. FY 2024 guidance somewhat below ours and the consensus numbers
>Operating performance with sales momentum and margin deterioration - Sales reached € 218m (-5% y-o-y vs +4% in Q3 and +8% in Q2), somewhat above our estimates but below the consensus. As regards its recent product launches: Ilumetri keeps on with its normalisation (+22% in Q4 +36% in Q3 and +39% in Q2) and Seysara maintains the deterioration observed over the last quarters (-19% vs -25% in Q3 and -26% in Q2 2023). The GM stood at 66% in Q4 2023 (flat y-o-y), in line ...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.